Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase.
Gomez, R., Jolly, S., Williams, T., Tucker, T., Tynebor, R., Vacca, J., McGaughey, G., Lai, M.T., Felock, P., Munshi, V., DeStefano, D., Touch, S., Miller, M., Yan, Y., Sanchez, R., Liang, Y., Paton, B., Wan, B.L., Anthony, N.(2011) Bioorg Med Chem Lett 21: 7344-7350
- PubMed: 22071300 
- DOI: https://doi.org/10.1016/j.bmcl.2011.10.027
- Primary Citation of Related Structures:  
3TAM - PubMed Abstract: 
Next generation NNRTIs are sought which possess both broad spectrum antiviral activity against key mutant strains and a high genetic barrier to the selection of new mutant viral strains. Pyridones were evaluated as an acyclic conformational constraint to replace the aryl ether core of MK-4965 (1) and the more rigid indazole constraint of MK-6186 (2). The resulting pyridone compounds are potent inhibitors of HIV RT and have antiviral activity in cell culture that is superior to other next generation NNRTI's.
Organizational Affiliation: 
Department of West Point Discovery Chemistry, Merck Research Labs., 770 Sumneytown Pike, PO Box 4, West Point, PA 19486-0004, USA. Robert_gomez@merck.com